Lifemd, Inc. (LFMD)
NASDAQ:LFMD
Want to see LFMD full AI Analyst Report?
Top Page
LifeMD
(NASDAQ:LFMD)
Select Model
Select Model
Rating:58Neutral
Price Target:
$4.50
▲(61.87% Upside)
Action:Reiterated
Date:05/09/26
LFMD’s score is driven by improving cash flow and a constructive operational outlook from reaffirmed 2026 guidance and strong subscriber/gross margin momentum, but it is held back by persistent GAAP losses and a TTM revenue downturn. Technicals are moderately positive short-to-intermediate term, while valuation is constrained by negative earnings and no dividend support.
Positive Factors
Improved Cash Generation
LifeMD has generated positive operating and free cash flow across 2023–TTM with a large TTM FCF increase. Sustained cash generation provides durable funding for marketing, pharmacy scale and product expansion, reducing near‑term financing risk and improving flexibility over the coming quarters.
Negative Factors
Ongoing GAAP Losses
LifeMD continues to report GAAP net losses and negative operating profit in recent periods; Q1 showed a $9.6M GAAP loss. Persistent accounting losses erode equity resilience, constrain optionality for reinvestment, and make sustained profitability reliant on execution and realization of projected adjusted EBITDA improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Cash Generation
LifeMD has generated positive operating and free cash flow across 2023–TTM with a large TTM FCF increase. Sustained cash generation provides durable funding for marketing, pharmacy scale and product expansion, reducing near‑term financing risk and improving flexibility over the coming quarters.
Read all positive factors
LifeMD (LFMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$209.41M
Dividend YieldN/A
Average Volume (3M)1.36M
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue Growth-6.23%
EPS Growth-25.01%
CountryUS
Employees304
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.41
Shares Outstanding48,362,510
10 Day Avg. Volume1,062,536
30 Day Avg. Volume1,359,186
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)6.65
Price to Sales (P/S)0.79
P/FCF Ratio24.01
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue0.83
Enterprise Value/Gross Profit0.96
Enterprise Value/Ebitda-42.14
Forecast
1Y Price Target
$9.00Price Target Upside223.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$222.09M
LifeMD Business Overview & Revenue Model
Company Description
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. T...
How the Company Makes Money
LifeMD primarily generates revenue from telehealth services sold directly to consumers. Key revenue streams typically include: (1) patient fees for virtual medical visits/consultations; (2) recurring subscriptions or membership fees for ongoing ca...
LifeMD Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call presents a constructive operational narrative: record subscriber additions, strong momentum in weight management and Women’s Health, meaningful gross margin expansion, growing pharmacy and insurance scale, and a clear roadmap to leverage AI for operating leverage. These positives are balanced against near-term profitability pressures from a front-loaded marketing push, a product‑mix transition from compounded to branded drugs that dampened near‑term revenue/unit economics, a wider GAAP net loss, and negative adjusted EBITDA in Q1. Management reaffirmed full-year guidance and outlined drivers for a second‑half EBITDA ramp (insurance coverage expansion, pharmacy economics, cross-sell, and marketing normalization), indicating confidence in the outlook despite short-term investments and transitions.Positive Updates
Revenue Ahead of Guidance
Q1 revenue of $50.2M, above guidance of $48M-$49M; full-year guidance reaffirmed at $220M-$230M (13%-19% YoY growth) with expected annualized run-rate revenue >$250M by Q4.
Negative Updates
Flat Year‑Over‑Year Revenue
Q1 revenue was essentially flat YoY at $50.2M versus $50.9M in the prior-year period, reflecting a product-mix shift (migration from compounded GLP-1s to branded drugs) that reduced near-term revenue per unit.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Ahead of Guidance
Q1 revenue of $50.2M, above guidance of $48M-$49M; full-year guidance reaffirmed at $220M-$230M (13%-19% YoY growth) with expected annualized run-rate revenue >$250M by Q4.
Read all positive updates
Company Guidance
Management reaffirmed full-year 2026 guidance of $220–$230 million in revenue (≈13–19% YoY) and $12–$17 million in adjusted EBITDA, and reiterated a goal of annualized run-rate revenue above $250 million and adjusted EBITDA above $25 million by Q4; Q2 guidance is $47–$50 million in revenue and adjusted EBITDA of negative $2 million to positive $1 million with a return to adjusted EBITDA profitability expected in H2. For context, Q1 actuals included $50.2 million revenue, ~42k net subscriber adds (ending >365k active subscribers, +~26% YoY), an adjusted EBITDA loss of ~$4.5 million, GAAP net loss of $9.6 million ($0.20/sh), gross profit $44.2 million with gross margin of 88% (up ~420 bps), selling & marketing $29.8 million, stock‑based comp $1.4 million, cash of $34.5 million, no debt and a $30 million undrawn revolver. Other operational metrics cited: ~100k weight‑management patients, ~215k RexMD active patients, pharmacy processing ~20k scripts/month from a 22.5k sq ft facility, ~112 million covered lives at quarter end (expected ~230 million by month‑end), CAC improved 4–5% sequentially as volumes rose from ~300–400 to 600–1,000 new patients/day, Women’s Health subscribers grew >7x from Q4 with on‑therapy retention >80%, RexMD personalized ED meds +>40% vs Q4, and marketing is expected at ~$26–27 million in Q2 with combined Q3–Q4 marketing of ~$42–44 million.LifeMD Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
56
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 219.42M | 194.06M | 212.45M | 152.55M | 119.03M | 92.88M |
| Gross Profit | 188.46M | 154.76M | 188.39M | 133.65M | 100.37M | 74.88M |
| EBITDA | -4.30M | -361.24K | -6.65M | -7.89M | -38.60M | -53.95M |
| Net Income | -16.25M | -7.11M | -18.88M | -20.60M | -45.54M | -60.90M |
Balance Sheet | ||||||
| Total Assets | 70.12M | 70.41M | 72.46M | 58.48M | 25.67M | 49.92M |
| Cash, Cash Equivalents and Short-Term Investments | 34.48M | 36.79M | 35.00M | 33.15M | 3.96M | 41.33M |
| Total Debt | 6.17M | 6.32M | 25.10M | 18.93M | 4.13M | 1.85M |
| Total Liabilities | 55.09M | 47.25M | 76.51M | 52.91M | 32.97M | 24.10M |
| Stockholders Equity | 15.04M | 23.16M | -5.49M | 3.51M | -6.83M | 26.85M |
Cash Flow | ||||||
| Free Cash Flow | 14.83M | 6.41M | 5.98M | 86.95K | -35.83M | -36.49M |
| Operating Cash Flow | 5.66M | 8.28M | 17.51M | 8.82M | -22.94M | -33.09M |
| Investing Cash Flow | 7.72M | 6.91M | -11.54M | -8.73M | -13.91M | -3.40M |
| Financing Cash Flow | -13.29M | -13.41M | -4.12M | 29.10M | -528.20K | 68.64M |
LifeMD Technical Analysis
Positive
2.78
Price Trends
3.42
Positive
3.51
Positive
5.41
Negative
Market Momentum
0.08
Negative
62.34
Neutral
68.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFMD, the sentiment is Positive. The current price of 2.78 is below the 20-day moving average (MA) of 3.73, below the 50-day MA of 3.42, and below the 200-day MA of 5.41, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 62.34 is Neutral, neither overbought nor oversold. The STOCH value of 68.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LFMD.
LifeMD Risk Analysis
LifeMD disclosed 45 risk factors in its most recent earnings report. LifeMD reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LifeMD Peers Comparison
UnderperformOutperform
Sector (51)
LFMD
LifeMD
4.33
-6.25
-59.07%
PETS
Petmed Express
2.23
-1.72
-43.54%
YI
111
5.79
-2.06
-26.24%
LifeMD Corporate Events
Business Operations and StrategyFinancial Disclosures
LifeMD Posts Q1 Results, Reaffirms 2026 Profitability Outlook
Positive
May 6, 2026
LifeMD reported first-quarter 2026 results on May 6, 2026, with revenue of $50.2 million, slightly below the prior year but above guidance, and an adjusted EBITDA loss of $4.5 million in line with expectations, driven by elevated, front-loaded mar...
Business Operations and StrategyExecutive/Board Changes
LifeMD Announces CFO Transition and Expanded Leadership Team
Positive
Mar 18, 2026
On March 16, 2026, LifeMD announced that Chief Financial Officer Marc Benathen would leave the company to pursue a new opportunity, remaining through March 31, 2026, and then serving in a paid transition advisory role for up to a year, while forfe...
Business Operations and StrategyFinancial Disclosures
LifeMD Issues 2026 Outlook Amid Strong 2025 Growth
Positive
Mar 9, 2026
LifeMD reported that for 2025 its revenue rose 25% to $194.1 million and adjusted EBITDA surged 309% to $15.3 million, while fourth-quarter revenue grew 4% to $46.9 million and adjusted EBITDA climbed 348% to $4.8 million. The company ended 2025 w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.